Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MediNet GroupHKSE:08161 43 EBITDA Margin % is 1.96% as of Mar. 2026, which is 60% below its 10-year median of 4.90. GuruFocus rates HKSE:08161 with a GF Score™ of 43/100 and a GF Value™ of HK$0.29 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 664 Healthcare Providers & Services companies, MediNet Group ranks worse than 62.35% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. MediNet Group's EBITDA for the
six
months ended in Mar. 2026 was HK$0.79 Mil. MediNet Group's Revenue for the
six
months ended in Mar. 2026 was HK$40.02 Mil. Therefore, MediNet Group's EBITDA margin for the quarter that ended in Mar. 2026 was 1.96%.
MediNet Group (HKSE:08161) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
MediNet Group EBITDA Margin % Related Terms
MediNet Group EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for MediNet Group's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:08161 vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, MediNet Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MediNet Group EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MediNet Group's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where MediNet Group's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MediNet Group (HKSE:08161) has a EBITDA Margin % of 1.96% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on MediNet Group and its competitors. This is 60% below median its historical median of 4.90. According to the industry distribution chart, MediNet Group ranks #414 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 62.3%.
Is MediNet Group's EBITDA Margin % too high?
MediNet Group's current EBITDA Margin % of 1.96% is 60% below median its 10-year median of 4.90. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. MediNet Group's value of 1.96% is 80.8% below this industry median. Based on the distribution chart, MediNet Group ranks #414 out of 664 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, MediNet Group has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MediNet Group's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, MediNet Group ranks #414 out of 664 companies for EBITDA Margin %. This places MediNet Group in the lower half of its industry. The industry median EBITDA Margin % is 10.21. MediNet Group's value of 1.96% is 80.8% below this benchmark. While the company's 10-year median is 4.90 vs. the industry median of 10.21, MediNet Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MediNet Group's current EBITDA Margin % of 1.96% is 80.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on MediNet Group and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MediNet Group's current EBITDA Margin % is 1.96%, which is 60% below median its own 10-year median of 4.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediNet Group stock overvalued right now?
Based on GuruFocus' analysis, MediNet Group (HKSE:08161) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.29, compared to a current price of HK$0.66 — trading 127.6% above its estimated fair value. The current EBITDA Margin % is 1.96%, which is 60% below median its 10-year median of 4.90 and 80.8% below the Healthcare Providers & Services industry median of 10.21. MediNet Group's overall GF Score™ is 43/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For MediNet Group (HKSE:08161), the current EBITDA Margin % is 1.96% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MediNet Group (HKSE:08161) Overvalued in 2026?
Based on GuruFocus' analysis, MediNet Group stock appears to be overvalued.
The current stock price of HK$0.66 is trading 127.6% above its estimated GF Value™ of HK$0.29.
GuruFocus considers MediNet Group to be Significantly Overvalued.
Key valuation signals for HKSE:08161:
EBITDA Margin %: 1.96% (60% below median its 10-year median of 4.90)
GF Value™: HK$0.29 vs. price of HK$0.66 (127.6% above fair value)
Industry Position: 80.8% below the Healthcare Providers & Services median (#414 of 664)
No single metric tells the full story. See the HKSE:08161 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MediNet Group Ltd is a provider of corporate healthcare solutions in Hong Kong. The company's operating segment includes the Dental business and the Medical business. The Dental segment offers dental solutions and dental services by dental clinics owned and operated by the group. Its Medical segment provides outpatient general services and men's health treatment services. It offers services to both plan members and self-paid patients. Geographically, the company generates the majority of its revenue from Hong Kong.
43GF Score
Get the complete analysis for HKSE:08161
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08161 has been successfully added to your 
